title: JAK/STAT disruption induces immuno-deficiency: Rationale for the development of JAK inhibitors as immunosuppressive drugs.
abstract: Cytokines are mediating immune cells responses through the activation of the JAK/STAT signaling pathway. Being critical for immune cells, a defective JAK/STAT signaling leads to various immune disorders, such as immunodeficiency. In contrast, hyperactivation of JAK/STAT signaling is linked to autoimmunity and cancer. Targeting the JAK/STAT proteins by small protein inhibitors impedes immune cell function by uncoupling cells from cytokine effects and by interfering with functional immune cell hallmarks, such as cell migration. This review will explore immune syndromes driven by JAK/STAT deregulation and discuss the emerging role of JAK inhibitors as immunosuppressive drugs used in autoimmunity and transplantation medicine.
authors.affiliation: Medical Clinic 3, Oncology, Hematology, Immunoncology and Rheumatology, University Clinic Bonn (UKB), Bonn, Germany.
authors.forename: Isabelle
authors.initials: I
authors.lastname: Cornez
authors.affiliation: Medical Clinic 3, Oncology, Hematology, Immunoncology and Rheumatology, University Clinic Bonn (UKB), Bonn, Germany.
authors.forename: Sowmya Parampalli
authors.initials: SP
authors.lastname: Yajnanarayana
authors.affiliation: Medical Clinic 3, Oncology, Hematology, Immunoncology and Rheumatology, University Clinic Bonn (UKB), Bonn, Germany.
authors.forename: Anna Maria
authors.initials: AM
authors.lastname: Wolf
authors.affiliation: Medical Clinic 3, Oncology, Hematology, Immunoncology and Rheumatology, University Clinic Bonn (UKB), Bonn, Germany; Laboratory for Tumorimmunology, Department of Medicine V, Medical University Innsbruck, Innsbruck, Austria. Electronic address: dominik.wolf@ukbonn.de.
authors.forename: Dominik
authors.initials: D
authors.lastname: Wolf
mesh_terms: D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology / Q000473:pathology; D002465:Cell Movement; D016207:Cytokines / Q000235:genetics / Q000276:immunology; D005786:Gene Expression Regulation; D006086:Graft vs Host Disease / Q000235:genetics / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000235:genetics* / Q000276:immunology / Q000473:pathology; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D053612:Janus Kinases / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000276:immunology; D009369:Neoplasms / Q000235:genetics / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D016377:Organ Transplantation; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D050791:STAT Transcription Factors / Q000235:genetics / Q000276:immunology; D015398:Signal Transduction
chemical_list: D016207:Cytokines; D007166:Immunosuppressive Agents; D047428:Protein Kinase Inhibitors; D050791:STAT Transcription Factors; D053612:Janus Kinases
keywords: Autoimmunity; GVHD; Immunosuppression; JAK; Myeloproliferative neoplasia; STAT